168 related articles for article (PubMed ID: 11828875)
1. A health care management company's experience with palivizumab.
Silverman W
Manag Care; 2002 Jan; 11(1):45-6. PubMed ID: 11828875
[No Abstract] [Full Text] [Related]
2. A health care management company's experience with palivizumab--1 year later.
Silverman W
Manag Care; 2003 May; 12(5):49-50. PubMed ID: 12800748
[No Abstract] [Full Text] [Related]
3. The cost and safety of multidose use of palivizumab vials.
Gooding J; Millage A; Rye AK; Lacroix R
Clin Pediatr (Phila); 2008 Mar; 47(2):160-3. PubMed ID: 17901213
[TBL] [Abstract][Full Text] [Related]
4. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
5. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
[No Abstract] [Full Text] [Related]
6. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.
Nuijten M; Lebmeier M; Wittenberg W
J Med Econ; 2009; 12(4):291-300. PubMed ID: 19811111
[TBL] [Abstract][Full Text] [Related]
7. Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab.
Meissner HC; Anderson LJ; Pickering LK
Pediatrics; 2004 Oct; 114(4):1082-4. PubMed ID: 15466107
[No Abstract] [Full Text] [Related]
8. Changing costs and the impact on RSV prophylaxis.
Smart KA; Paes BA; Lanctôt KL
J Med Econ; 2010; 13(4):705-8. PubMed ID: 21087075
[TBL] [Abstract][Full Text] [Related]
9. [Prophylaxis of respiratory syncytial virus infections with palivizumab].
Danés Carreras I; Arnau De Bolós JM
An Esp Pediatr; 2002 Apr; 56(4):289-91. PubMed ID: 11927094
[No Abstract] [Full Text] [Related]
10. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.
Krilov LR; Weiner LB; Yogev R; Fergie J; Katz BZ; Henrickson KJ; Welliver RC
Pediatrics; 2009 Dec; 124(6):1682-4. PubMed ID: 19948634
[No Abstract] [Full Text] [Related]
11. Cost effectiveness of palivizumab in children with congenital heart disease in Germany.
Nuijten M; Lebmeier M; Wittenberg W
J Med Econ; 2009; 12(4):301-8. PubMed ID: 19811110
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE; Mahle WT
Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Mahadevia PJ; Malinoski FJ
Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
[No Abstract] [Full Text] [Related]
14. [Respiratory syncytial virus infections and preventive options].
Moll HA; de Groot R
Ned Tijdschr Geneeskd; 2000 Apr; 144(15):724-5. PubMed ID: 10778722
[No Abstract] [Full Text] [Related]
15. [Prophylaxis against RS virus infection].
Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
Lakartidningen; 2002 Jan; 99(3):170-1. PubMed ID: 11838073
[No Abstract] [Full Text] [Related]
16. [Polivizumab against respiratory syncytial virus?].
Brunvand L
Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2570-2. PubMed ID: 11070999
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Reeve CA; Whitehall JS; Buettner PG; Norton R; Reeve DM; Francis F
J Paediatr Child Health; 2006 May; 42(5):253-8. PubMed ID: 16712554
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis.
Rodríguez SP; Fariña D; Bauer G
Pediatr Infect Dis J; 2008 Jul; 27(7):660-1. PubMed ID: 18520447
[TBL] [Abstract][Full Text] [Related]
19. Immunoprophylaxis of respiratory syncytial virus infection.
Simoes EA
Indian Pediatr; 2000 Mar; 37(3):243-7. PubMed ID: 10750065
[No Abstract] [Full Text] [Related]
20. Health economics and RSV.
Carbonell-Estrany X; Lázaro y de Mercado P
Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():12-3. PubMed ID: 19651392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
